Spirax Gets Punished for Being Merely Good

Spirax Gets Punished for Being Merely Good

Mark Nichols

Tue, August 11, 2026 at 6:18 PM GMT+3 4 min read

• SPXSY -3.44%

THE GIST

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Spirax did what it said it would do. The problem is investors wanted it to do more. Shares slid because the industrial engineer delivered progress without raising the bar, and in this market, "steady" can still get you whacked.

WHAT HAPPENED

Spirax shares fell as much as 10% after the group reported first-half results and left its full-year guidance unchanged.

Revenue rose 5% to £863.8 million (about $1.2 billion) in the six months to June 30, comfortably ahead of the company's internal benchmark for industrial production growth of around 1.5%.

Statutory operating profit jumped 44% to £154.2 million, helped by a comparison with restructuring costs taken last year. On an adjusted basis, operating profit rose 8% to £171.1 million, while adjusted pre-tax profit increased 9% to £152 million.

Adjusted operating margin ticked up to 19.8%, from around 19.3% to 19.7% depending on the measure used. The company reiterated guidance for mid-single-digit organic revenue growth and full-year margin progress, with management expecting the margin to move above 20%. All three divisions grew.

Electric Thermal Solutions was the strongest, with sales up 11% as semiconductor demand improved. Watson-Marlow Fluid Technology Solutions grew 7%, helped by better momentum in biopharma. Steam Thermal Solutions, which accounts for around half of group sales, grew just 1%, weighed down by shipment phasing and weaker project activity in China.

Cash conversion softened to 54% from 61%, partly due to seasonal timing and planned inventory builds. The interim dividend rose 3% to 50.4p.

CEO Nimesh Patel said Spirax had delivered resilient growth ahead of industrial production and pointed to momentum in semiconductors and biopharma heading into the second half.

WHY IT MATTERS

Spirax is a classic "quality industrial" stock learning a classic quality-stock lesson: valuation matters when momentum disappoints.

The company did not have a bad half. It grew revenue, improved profits, lifted margins, raised the dividend and kept guidance intact. That would usually count as a solid update. But Spirax has historically been priced for something better than solid.

This is a business investors have liked because of its specialist engineering niches, high-margin aftermarket revenue and exposure to resilient industrial processes. Steam systems, thermal energy equipment and fluid technology are not fashionable in the same way as AI chips or obesity drugs, but they are embedded in industries that need reliability more than hype. That's the appeal. The trouble is that the recovery is uneven.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Electric Thermal Solutions is doing the heavy lifting. Semiconductor demand helped sales rise sharply, and margins improved. Watson-Marlow also looks healthier, with biopharma orders improving and second-quarter orders reportedly at their highest level since the pandemic peak.

Those are encouraging signs. They suggest two important end markets are turning in Spirax's favor. But Steam Thermal Solutions is still dragging.

That division is too big to ignore. It drives about half of group sales, and its margin fell as shipment timing and weak Chinese project activity weighed on performance. Until the steam business starts to accelerate, the group recovery will feel incomplete. That explains the market reaction.

Investors were not selling because Spirax missed badly. They were selling because the results did not justify a more optimistic outlook. After a recent recovery in the share price, "no upgrade" became the disappointment.

There is also a margin memory problem. Spirax's group margin is heading back above 20%, but the business used to earn much more. Investors' Chronicle noted that margins were above 25% four years ago. So even though today's margin progress is real, it still looks like recovery rather than full restoration.

That matters for the valuation. The shares trade below their long-term average earnings multiple, but they are not obviously cheap if the old margin structure does not return.

In other words, Spirax is no longer being judged just on whether it is improving. It is being judged on how much of the old Spirax can come back.

Management's medium-term targets remain intact. The company says it is on track. End markets like semiconductors and biopharma are improving. Cost actions are helping. The balance of the second half should benefit from higher shipments.

But investors have heard enough "on track" stories this earnings season. They want proof that progress is turning into upgrades.

Spirax still looks like a strong engineering business. The market just wanted it to sound a little less patient.

WHAT'S NEXT

Investors will watch whether second-half shipments lift margins above 20%, whether Watson-Marlow's biopharma recovery continues and whether Electric Thermal Solutions can keep riding semiconductor demand.

The key test is Steam Thermal Solutions. If that division starts growing properly again, the group recovery looks much more convincing. Spirax has shown the machine is running. Now it needs to show it can build steam.